Swiss pharmaceutical giant Roche said sales had soared 7.0 percent to 11.6 billion francs (7.67 billion euros, 10.13 billion dollars) in the first quarter of 2009, outstripping the global market.
The Basel-based group said sales at its pharmaceutical division grew 8.0 percent to 9.21 billion francs, driven by its oncology, inflammation and ophthalmology portfolios.
Sales at its diagnostics division also rose 3.0 percent to 2.36 billion francs.
Roche chief executive Severin Schwan said: "Sales in both divisions continued to grow significantly faster than their respective markets. We are therefore confident that we can achieve our full-year targets."
He added that the group would update its full-year outlook when it reported its first-half results in July to include the impact of the group's buyout of US biotechnology unit Genentech.
Roche last month agreed to pay 46.8 billion dollars to take full control of Genentech.